Document is current
Any future updates will be listed below
-
Authors
Noringriis, Inge Mansfield https://orcid.org/0000-0001-7802-2099
Donia, Marco https://orcid.org/0000-0003-4966-9752
Madsen, Kasper
Schmidt, Henrik
Haslund, Charlotte Aaquist
Bastholt, Lars
Svane, Inge Marie https://orcid.org/0000-0002-9451-6037
Ellebaek, Eva
- License Information
-
More Information
Article History
Received: 12 February 2025
Revised: 22 April 2025
Accepted: 29 April 2025
First Online: 26 May 2025
Competing interests
: Within the last two years: MD has received proprietary data access from Bristol Myers Squibb and Genentech and is an advisor of Achilles Therapeutics. HS has received a research grant from MSD. CAH has received honoraria for lectures from BMS, AstraZeneca, and GSK, as well as consultancies for AstraZeneca. IMS has received honoraria for consultancies and lectures from IO Biotech, Novartis, MSD, Pierre Fabre, BMS, Novo Nordisk, TILT Bio; research grants from IO Biotech, BMS, Lytix, Adaptimmune, and TILT Bio. EE has received honoraria from BMS, Pierre Fabre, Novartis, and MSD for consultancies and lectures, and from MSD and Pierre Fabre for travel and conference support. The remaining authors declare no competing interests.
: DAMMED is approved by the Danish Patient Safety Authority (approval number 18/47885) and this study was approved by the Danish Data Protection Agency (approval number P-2022-281). Written informed consents are obtained from all participants. This study was performed in accordance with the Declaration of Helsinki.
